

1 **Title**

2 Strategic validation of variants of uncertain significance in *ECHS1* genetic testing

3

4 **Running title**

5 VUS validation in *ECHS1* genetic testing

6

7 **Authors**

8 Yoshihito Kishita^{1,2,12}, Ayumu Sugiura^{2,12}, Takanori Onuki³, Tomohiro Ebihara⁴, Tetsuro
9 Matsushashi³, Masaru Shimura³, Takuya Fushimi³, Noriko Ichino², Yoshie Nagatakidani¹,
10 Hitomi Nishihata¹, Kazuhiro R Nitta², Yukiko Yatsuka², Atsuko Imai-Okazaki², Yibo Wu^{5,6},
11 Hitoshi Osaka⁷, Akira Ohtake^{8,9}, Kei Murayama^{3,10}, Yasushi Okazaki^{2,11,*}

12

13 **Affiliations**

14 ¹Department of Life Science, Faculty of Science and Engineering, Kindai University,
15 Osaka, Japan

16 ²Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research
17 Center, Juntendo University, Graduate School of Medicine, Japan

18 ³Department of Metabolism, Chiba Children's Hospital, Chiba, Japan

19 ⁴Department of Neonatology, Chiba Children's Hospital, Chiba, Japan

20 ⁵University of Geneva, Geneva, Switzerland.

21 ⁶YCI Laboratory for Next-Generation Proteomics, RIKEN Center of Integrative Medical
22 Sciences, Kanagawa, Japan

23 ⁷Department of Pediatrics, Jichi Medical University, Tochigi, Japan

24 ⁸Department of Pediatrics & Clinical Genomics, Faculty of Medicine, Saitama Medical
25 University, Saitama, Japan

26 ⁹Center for Intractable Diseases, Saitama Medical University Hospital, Saitama, Japan

27 ¹⁰Center for Medical Genetics, Chiba Children's Hospital, Chiba, Japan

28 ¹¹Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative
29 Medical Sciences, Yokohama, Kanagawa, Japan

30 ¹²These authors contributed equally

31 *Corresponding author: ya-okazaki@juntendo.ac.jp

32

1 **Abstract**

2 *ECHS1* is the causative gene for mitochondrial short-chain enoyl-CoA hydratase 1
3 deficiency. While genetic analysis studies have diagnosed numerous cases with *ECHS1*
4 variants, the increasing number of variants of uncertain significance (VUS) in genetic
5 diagnosis is a major problem. Therefore, we constructed an assay system to verify VUS
6 function. A high-throughput assay using *ECHS1* knockout cells was performed to index
7 these phenotypes by expressing cDNAs containing VUS. The functional validation of
8 VUS identified novel variants causing loss of *ECHS1* function. Moreover, we identified
9 cases with functional *ECHS1* defects through multi-omics analysis. We identified a
10 synonymous substitution, p.P163=, and candidate pathogenic variants in the above
11 validation experiments. In summary, this study uncovered new *ECHS1* cases based on
12 VUS validation and omics analysis; these analyses are applicable to functional
13 evaluation of other genes associated with mitochondrial disease.

14

15 **Keywords**

16 Variants of uncertain significance, Mitochondrial disease, RNA-seq, High-throughput
17 assay, Multi-omics

1 Introduction

2 *ECHS1* encodes short-chain enoyl-CoA hydratase 1 (SCEH), responsible for the
3 degradation of branched chain amino acids and fatty acids (Sharpe & McKenzie, 2018).
4 Abnormalities in valine metabolism particularly impact the pathogenesis of SCEH
5 deficiency (MIM #616277); accumulation of valine metabolites such as S-(2-carboxy-
6 ypropyl) cysteine (SCPC) and S-(2-carboxypropyl) cysteamine (SCPCM) derived from
7 methacrylyl-CoA, and S-(2-carboxyethyl) cysteine (SCEC), S-(2-carboxyethyl)
8 cysteamine (SCECM), and 2-methyl-2,3-dihydroxybutyric acid (MDHB), derived from
9 acryloyl-CoA, is often observed (Peters *et al*, 2014). Mutations in *ECHS1* mainly cause
10 Leigh encephalopathy with patients presenting elevated plasma lactate and brain
11 magnetic resonance imaging (MRI) abnormalities (Peters *et al*, 2015; Yamada *et al*,
12 2015; Haack *et al*, 2015a; Sakai *et al*, 2015; Tetreault *et al*, 2015). In addition,
13 mitochondrial respiratory chain complex abnormalities have also been reported to cause
14 mitochondrial dysfunction in cases with *ECHS1* mutations (Sakai *et al*, 2015; Haack *et al*,
15 2015a; Tetreault *et al*, 2015). Numerous Japanese cases with *ECHS1* mutations have
16 also been reported (Sakai *et al*, 2015; Haack *et al*, 2015a; Yamada *et al*, 2015; Ogawa
17 *et al*, 2017, 2020). Numerous *ECHS1* variants have been reported, among which,
18 pathogenic variants exist in various genetic regions. A variant frequently reported in
19 Asians is Asn59Ser. The expansion in the clinic of genetic testing has resulted in the
20 rapid accumulation of variants of uncertain significance (VUS). Mitochondrial diseases
21 are no exception, and the VUS number in *ECHS1* is increasing. On the other hand,
22 recent studies have also shown that a valine-restricted diet is effective for cases with
23 *ECHS1* mutations (Yang & Yu, 2020; Sato-Shirai *et al*, 2021). Quick diagnosis is
24 important for early treatment of SCEH deficiency.

25 Recently, various approaches have been tried to solve VUS. Functional analysis using
26 cultured cells and model organisms is a powerful validation method, providing strong
27 evidence of pathogenicity according to the American College of Medical Genetics and
28 Genomics (ACMG) guidelines (Richards *et al*, 2015). Especially, high-throughput assays
29 and assay methods combining CRISPR/Cas9 and genome-sequencing technologies are
30 being used for VUS verification in cancer-causing genes (Findlay *et al*, 2018; Kweon *et al*,
31 2020). Although VUS have been validated for *IVD*, *ACADVL*, and *ACAD9*, all
32 causative genes of inborn errors of metabolism (D'Annibale *et al*, 2021; Xia *et al*, 2021;
33 D'Annibale *et al*, 2022), there is little research on VUS verification in rare diseases.

34 In this study, we focused on VUS in *ECHS1*, common in many cases of mitochondrial
35 diseases (Kohda *et al*, 2016; Ogawa *et al*, 2017, 2020). In Japan, Tohoku Medical
36 Megabank has a genome project for healthy subjects (Tadaka *et al*, 2019, 2021). In

1 recessive diseases, the causative variant is often present at a certain frequency within a
2 given race. Therefore, in addition to the VUS found in previous our studies of patients
3 with mitochondrial diseases, we conducted a variant validation of rare variants registered
4 in the Japanese Multi-Omics Reference Panel (jMorp).

5 Here, we constructed an assay system with ATP measurement using cells deficient in
6 the *ECHS1* gene for systematic VUS verification and validation of heterozygotic variants.
7 Furthermore, we found a novel *ECHS1* variant by multi-omics analysis. Coincidentally,
8 the newly found variants were verified by the assay system as being caused by *ECHS1*.

9 10 **Results**

11 Cases with *ECHS1* variants

12 In previous genomic studies, gene panel sequencing and whole exome sequencing led
13 to the discovery of 15 variants in *ECHS1* cases (Table 1). In Japanese people, the most
14 frequently identified variant was Asn59Ser, followed by Ala2Val (Haack *et al*, 2015b;
15 Sakai *et al*, 2015; Ogawa *et al*, 2020) (Table 1 and Fig. 1). These variants are common
16 in other Asian cases; the allele frequencies of Asn59Ser and Ala2Val are 0.0005769 and
17 0.0001927 in the gnomAD v3.1.2 East Asian, respectively. Several of these cases also
18 had VUS in ClinVar (as of 20220715, and the same afterhere), such as Met1Val and
19 Leu8Pro (Ogawa *et al*, 2017; Uchino *et al*, 2019). In addition, we also found
20 heterozygous variants in *ECHS1* with conflicting interpretations of pathogenicity
21 (Thr266Ala and Ala278Thr), VUS (Arg272Gln), or unreported (Ala268Thr). All these
22 variants are rare and may be disease-causing, but no experimental verification of the
23 variants has been performed so far. Variants with low allele frequency have been
24 identified, and a number of them have been designated as VUS. Accurate and quick
25 interpretation of these variants is essential for improved diagnosis.

26 27 VUS validation in *ECHS1*

28 To perform VUS validation of *ECHS1*, we first generated cells deficient in the *ECHS1*
29 gene by targeting *ECHS1* using the CRISPR/Cas9 system in HEK293FT cells. The
30 *ECHS1* KO cell line had an in-frame deletion of 18 bases in exon 2 of the *ECHS1* gene
31 (Fig. 2A). This in-frame deletion resulted in loss of *ECHS1* mRNA and protein, as
32 confirmed by qRT-PCR and western blotting (Fig. 2B). We also detected abnormalities
33 in the mitochondrial function in *ECHS1* KO cells. In galactose medium, ATP production
34 is largely dependent on mitochondrial respiration (Robinson *et al*, 1992). Accordingly, we
35 measured ATP levels of wild-type (WT) and *ECHS1* KO cells after incubation in glucose
36 and galactose media. The ratio of ATP levels under galactose and glucose conditions

1 was stable, and no significant difference was observed between *ECHS1* KO and WT
2 cells under these conditions (Fig. 2C). The cellular toxicity of *ECHS1* deficiency is due
3 to accumulation of intermediates in valine metabolism. That explains why a valine-
4 restricted diet is recommended to patients harboring *ECHS1* pathogenic variants (Sato-
5 Shirai *et al*, 2021). Consistently, valine addition to the galactose medium lead to further
6 reduced ATP level in *ECHS1* KO cells, in a dose-dependent manner (Fig. 2D). These
7 results suggest that the abnormal mitochondrial function in *ECHS1* KO cells results from
8 the abnormal valine metabolism, as shown in human patients, making it a suitable model
9 to validate VUS of *ECHS1*. Accordingly, we performed a functional verification of VUS
10 using *ECHS1* KO cells expressing VUS.

11 First, variants identified from previous genomic studies and from jMorp were selected for
12 functional validation. The targets were 15 variants identified by our genome analysis and
13 six rare variants registered in jMorp (4.7KJPN released on 20190902; Fig. 1 and Table
14 S1). The Leu8Pro and Asn59Ser variants were found in our patients as well as registered
15 in jMorp (4.7KJPN). Other four variants were not identified in our genome analysis of
16 mitochondrial disease patients. *ECHS1* is a mitochondria-localized protein with a
17 mitochondrial targeting sequence (MTS) at the N-terminal. Four variants were located at
18 the translation initiation site and the MTS. We compared *ECHS1* KO cells transfected
19 with an empty vector and *ECHS1* WT cDNA to *ECHS1* KO cells transfected with an
20 *ECHS1* gene including VUS.

21 Exogenously expressed *ECHS1* shows uncleaved and cleaved forms (Fig. 3A, single
22 and double asterisks, respectively). Some variants were dominantly expressed in an
23 uncleaved form. Further, we found a significant decrease in the expression level of
24 variants in the MTS and at leucine 145 (Fig. 3A).

25 Next, we examined VUS functions in the mitochondria. *ECHS1* WT expression restored
26 ATP levels in *ECHS1* KO cells (Fig. 3B). The ATP expression of KO cells transfected with
27 each variant was compared with that for KO cells transfected with empty vector or
28 transfected with WT vector; changes in ATP levels were evaluated by one-way ANOVA
29 followed by Dunnet's test (Fig. 3C). In addition to Ala2Val and Asn59S, reported as
30 pathogenic variants, the two VUS with altered start codons failed to restore ATP levels
31 probably due to significantly reduced protein expression (Fig. 3B). A marked down-
32 regulation in protein levels was observed, with Leu8Pro showing a significant reduction
33 in the lower band considered to correspond to mature *ECHS1* (Fig. 3A). His119Gln,
34 Pro163Leu, Ala268Thr, and Ala278Thr variants had higher expression levels, but failed
35 to fully improve ATP levels equivalent to WT, suggesting that these variants were
36 deleterious (Fig. 3B).

1 Although Leu8Pro and Phe33Ser were reported as pathogenic variants (Kohda *et al*,
2 2016; Uchino *et al*, 2019), ATP assays demonstrate a mild functional decline. Since
3 Leu8Pro and Phe33Ser were identified as a compound heterozygote with Asn59Ser, a
4 nonfunctional variant (Fig. 3B), we hypothesized that Leu8Pro and Phe33Ser might be
5 mild deleterious variants capable of restoring KO cells but not KO cells expressing highly
6 toxic variants. To test this hypothesis, we reproduced compound heterozygous
7 genotypes by transfecting *ECHS1* KO cells with two different variants (Fig. 4A). The ATP
8 assay demonstrated that WT restored KO cells upon co-transfection with Asn59Ser,
9 whereas, as expected, all three variants tested did not show recovery (Fig. 4B and C).
10 Our system is valuable to validate the pathogenic nature of the compound heterozygous
11 state.

12

13 Validation of *ECHS1* variants from omics analysis

14 In case 1, a Thr266Pro variant was identified; in case 2, an Ala268Thr variant was
15 identified; in cases 3 and 4, a Ala278Thr variant was identified; in case 5, an Ala278Val
16 variant was identified (Table 2, Fig. S2). In addition, these cases also had a Pro163=
17 variant, identified in a Samoan family and a very frequent variant (0.01156) in gnomAD
18 v3.1.2 East Asian populations, and suggested to exhibit splicing abnormalities (Simon *et*
19 *al*, 2021). In the present study, RNA-seq analysis was performed on case 1 and case 4.
20 Then, we identified sequence reads showing exon skipping as consequence of the
21 Pro163= variant (Fig. 5A). To examine whether exon skipping actually increased in cases
22 with Pro163=, we plotted RNA-seq counts of the *ECHS1* gene and the number of
23 detected reads showing exon skipping (Fig. 5B). We analyzed 26 RNA-seq data,
24 including case 1 and case 4, as well as one case with heterozygous Pro163=; exon
25 skipping increased in these samples. In addition, after counting the allele numbers at the
26 Thr266Pro and Ala278Thr variant positions showed a bias in allele expression (Fig. 5C).
27 This indicates that the significantly reduced expression of alleles with Pro163= in case 1
28 and case 4 fibroblasts. Furthermore, proteome analysis in case 1 fibroblasts confirmed
29 a significant decrease in *ECHS1* expression (Fig. 6A). In addition, protein expression in
30 case 1 fibroblasts was confirmed by sodium dodecyl sulfate polyacrylamide gel
31 electrophoresis (SDS-PAGE) followed by Western blot (WB), revealing a marked decrease
32 in protein expression (Fig. 6B). Furthermore, previous studies experimentally
33 demonstrated that case 4 leads to decreased *ECHS1* expression and enzymatic activity,
34 as well as accumulation of intermediate products of valine metabolism (Kuwajima *et al*,
35 2021). We here concluded that and non-synonymous substitution combinations are
36 disease-causing in these cases.

1

2 **Discussion**

3 *ECHS1* is one of the most frequent genes found in patients with mitochondrial diseases.
4 In addition to our genetic study(Haack *et al*, 2015b; Ogawa *et al*, 2017, 2020), *ECHS1*
5 has been reported as a frequent cause of mitochondrial disease in genetic studies of
6 Leigh encephalopathy in Asian countries such as China(Stenton *et al*, 2022) and
7 Korea(Lee *et al*, 2020). The length of the coding region is 873 bp. About 250 variants
8 have been reported in ClinVar, of which about 40 are pathogenic/likely pathogenic and
9 nearly 80 have been registered as VUS or with conflicting interpretations of pathogenicity.
10 However, the molecular mechanism by which *ECHS1* variants cause disease is poorly
11 understood. In this study, we established a system to functionally validate *ECHS1*
12 variants, finding some potential pathogenic variants.

13 Resolving VUS is a major challenge in various diseases, because VUS continue to
14 accumulate under the circumstances where genome analysis is becoming more
15 common. Genome sequence projects in healthy individuals have revealed allele
16 frequencies in various races. The accumulation of genome analysis information is
17 expected to lead to the discovery of novel pathogenic variants, since rare variants also
18 found in healthy individuals can be pathogenic. Against this background, it may be
19 possible to make a proactive evaluation of variants not yet been associated with disease.
20 Based on the above, we could identify novel pathogenic variants in this study.
21 Furthermore, the combination of RNA-seq, proteomics and conventional genomic
22 analysis enabled a reliable diagnosis.

23 *ECHS1* is a nuclear-encoded gene transported to mitochondria by the MTS(Burgin &
24 McKenzie, 2020). MTS locates at the N-terminus and is cleaved in mitochondria by
25 mitochondrial proteases(Vaca Jacome *et al*, 2015). There are three points involved in
26 pathogenicity: 1) expression, 2) location, and 3) function. It was reported that *ECHS1* is
27 degraded through ubiquitin-proteasome pathway in cancer cells (PMID: 34615856). As
28 shown in Fig. 2A, Met1Ala, Met1Thr, and Ala2Val were weakly expressed. Consistently,
29 these variants failed to restore ATP decrease in *ECHS1* KO cells. Since inhibition of
30 proteasome degradation by MG132 had no effect on the protein level of all *ECHS1*
31 variants tested in this study (Fig. S1), these substitutions may alter the expression level
32 at the transcriptional or translational level. The Leu8Pro variant was detected dominantly
33 in the uncleaved form (Fig. 3A), suggesting mis-targeting to mitochondria. Leu145Pro
34 was also weakly expressed, but increased expression with higher amount of transfection
35 did not restore. As with Asn54Ser, Leu145Pro is a functionally disrupted variant.
36 Interestingly, Leu145Pro, a variant reported only in jMorp and not previously identified in

1 patients with the disease, had a high molecular weight. It is expected to be reported in
2 Japanese case with this variant. We propose that those who identify variants in *ECHS1*
3 by genetic test will refer to our variant evaluation study as evidence and that this will lead
4 to a solution to the cause of the disease in the future.

5 Leu8Pro and Phe33Ser, considered “Likely benign” variants from VUS validation
6 experiments (Fig. 3B and C), were validated by co-expressing with the Asn59Ser variant
7 (Fig. 4B and C). By validating the assumption of complex heterozygosity in combination
8 with a pathogenic variant, we could obtain data accurately reflecting the functional
9 evaluation of hypomorphic variants. The assay was effective for variants in the borders,
10 for which very subtle validation results were obtained. Despite its higher experimental
11 complexity, the assay can be performed while maintaining the conventional throughput,
12 and the validation targets can be expanded. In our reported *ECHS1* mutant cases, the
13 most common combination of is Asn59Ser and Ala2Val. However, since Asn59Ser has a
14 higher allele frequency than Ala2Val, cases homozygous for Asn59Ser should be more
15 frequent; however, no patients homozygous for Asn59Ser have been found. This
16 suggests that Asn59Ser may be so harmful that in homozygosity it may result in severe
17 developmental abnormalities in the prenatal period. The high number of Asn59Ser and
18 Ala2Val combinations may be due to Ala2Val having a smaller functional loss than
19 Asn59Ser, as shown experimentally in this study. Asn59Ser is only viable in a compound
20 heterozygous state with less toxic variants. The combination with milder variants such
21 as Leu8Pro and Phe33Ser, verified in this study, might allow normal development until
22 birth. In other words, this combined assay could first accurately indicate functional
23 abnormalities for variants with abnormalities intermediate between normal and
24 completely defective, being a very effective and essential method for variant evaluation.
25 Mostly, in silico predictions and experimental validation of most variants are comparable.
26 On the other hand, silico predictions for some variants differ from our validation
27 experiments; therefore, validation experiments are important for such variants. For
28 example, Ala2Val, already been reported as pathogenic, was not highly damaging in in
29 silico predictions (Table S1). However, the validation results suggest that although the
30 experimental data indicate an effect on protein gene expression itself, the functional
31 effect may not be as significant. A similar trend was observed for Leu8Pro, expected to
32 have a significant effect on protein localization but relatively little effect on protein function.
33 His119Gln was also rated mostly tolerant or benign in silico, but experimental validation
34 suggested that the variant affects gene function. The major achievement of this study is
35 providing quantitative experimental validation data for each variant on the same
36 functional platform. We are expanding the validation of other genes; in particular, VUS

1 validation of genes involved in respiratory chain complex I confirmed this to be a
2 reproducible and efficient analysis.
3 In this validation, we focused on variants specific to Japanese and Asian populations.
4 Naturally, this should be further expanded to include variants from other ethnicities. Our
5 assay system is based on a very simple method and can easily be expanded to other
6 VUS, by including gnomAD and ClinVar variants. In the present study, VUS was verified
7 for jMorp (4.7KJPN) variants, but since then, the jMorp data has been updated and the
8 number of registrations has increased. While planning our validation experiment, the
9 variant data of 4.7K JPN were registered, from which we extracted variants with very low
10 allele frequencies (Table S2). However, there are now 38K JPN, with 20 more
11 registrations from our validated variants. The data is being updated at an accelerated
12 pace, with 14KJPN in 2021 and 38KJPN in 2022. Given the constant updates to the
13 database, it is important to verify these variants in the future.
14 ECHS1 protein loss is considered to have a threshold of 30–40% for disease(Simon *et*
15 *al*, 2021). This is shown by the analysis with Pro163= and Ala278Thr from the study of
16 Simon et al. Those homozygous for Pro163= did not develop the disease, despite
17 showing a protein expression around 40%. On the other hand, the combination of
18 Pro163= and Ala278Thr showed <30% protein expression and developed the disease.
19 Ala278Thr is considered highly toxic, as it was found to be deleterious in the VUS
20 validation experiment. Although Ala278Val has not been validated, we think it likely to be
21 as deleterious as Ala278Thr since many scores in silico also indicated damaging effects.
22 For Thr266Pro, no significant decrease in ATP levels was observed in VUS validation.
23 However, abnormalities at the protein level were evident from the proteome and
24 immunoblotting. VUS expression experiments with the Thr266Pro variant also showed
25 reduced ECHS1 expression (Fig. 3A). Considering these results, Thr266Pro might have
26 less functional loss and more impact on protein expression. In addition, the forced
27 expression system showed a protein decrease not expected to significantly reduce ATP
28 levels. In protein expression validation (Fig. S1), the amount of mature ECHS1
29 synthesized from Thr266Pro was lower than that of immature ECHS1, suggesting that
30 this variant has a significant effect on protein expression and maturation. For Ala268Thr,
31 a mild decrease in ATP levels was observed. Since the value of Ala268Thr was similar
32 to that of Pro163Leu, reported as likely pathogenic in ClinVar, Ala268Thr was considered
33 to have an effect on protein function. Case 2 with the Ala268Thr variant had later onset
34 and milder symptoms than other ECHS1 cases, suggesting that the variant itself has a
35 milder effect. Pro163=, despite its high allele frequency [0.01156 in gnomAD v3.1.2 East
36 Asian, 0.00789 in the jMorp (38KJPN)], is a possible causative variant; its combination

1 with other pathogenic variants leads to disease development. We found four cases with
2 Pro163= and other rare variant in this study. There have been very few reports of such
3 a high frequency variant in studies of mitochondrial diseases; this variant might be
4 responsible for the increased frequency of cases with ECHS1 mutations. However,
5 variants without amino acid substitutions have been overlooked as benign in previous
6 genetic diagnosis. Given the high potential number of patients with Pro163=, it is
7 expected that the number of cases with Pro163= will further increase because of our
8 findings.

9 Our VUS verification system has some limitations. Even pathogenic variants may be
10 missed in this experimental system. In fact, Pro163Leu, registered as likely pathogenic
11 in ClinVar, showed a mild score. Thus, variants with intermediate ratings could be
12 pathogenic. In such cases, it would be necessary to validate them using an assay system
13 that assumes compound heterozygosity. Moreover, since this is a forced expression
14 system, variants that cause protein stability or splicing abnormalities may be missed. To
15 extract these variants, other assay systems and functional experiments using patient
16 specimens are required.

17 18 **Materials and methods**

19 Cell culture and knockout cell generation

20 Cells were cultured at 37°C and 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM
21 with 4.5 g/L glucose; Nacalai Tesque) supplemented with 10% fetal bovine serum and
22 1% penicillin–streptomycin.

23 Single guide RNAs (sgRNAs) were designed using CRISPRdirect software (Naito *et al*,
24 2015).he target sequence was as follows: 5'-GGGCCTTGGGGCGGTTCACT-3'. gRNA
25 oligonucleotides were inserted into a pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene
26 62988) plasmid as previously described(Ran *et al*, 2013). HEK293FT cells were
27 transfected with PX459 including *ECHS1* targeted sgRNA. Cells were selected using 2
28 µg/mL puromycin and single cells were isolated. Genomic DNA was extracted from
29 isolated cells, and sgRNA target sites were amplified using KOD FX Neo (Toyobo).
30 Primer sequences are as follows: 5'-CCCATGACCGTCTTCACTCG-3' and 5'-
31 ACATCCCTTCCCCACTCTC-3'. PCR products were purified and directly sequenced.

32 33 Vector construction

34 cDNA of *ECHS1* (NM_00492) WT and VUS were synthesized and inserted into
35 pCDNA3.1 Lifect-EGFP (Addgene 67303) with HindIII and XbaI sites by GENEWIZ/
36 Azenta.

1

2 ATP assay

3 HEK293FT WT or *ECHS1* knockout cells were seeded in a collagen-coated 96-well plate
4 (354650, Corning, AZ, USA) at 1×10^4 cells/well with growth medium containing 25 mM
5 glucose. For VUS validation, *ECHS1* knockout cells were transfected with 20 ng of
6 expression vectors encoding WT or *ECHS1* variants. One day after plating or
7 transfection, the medium was replaced with 25 mM glucose or 10 mM galactose medium
8 supplemented with dialyzed 10% fetal bovine serum (04-011-1A, Biological industries,
9 KibbutzBeit-Haemek, Israel) and L-valine (13046-62, Nacalai Tesque, Kyoto, Japan).
10 Four days after culture in galactose or glucose medium, the ATP content was measured
11 using the CellTiter-Glo® Luminescent Cell Viability Assay kit (Promega) with a VICTOR
12 Nivo multimode microplate reader (PerkinElmer, MA, USA).

13

14 RNA-seq

15 RNA was purified from fibroblasts by the Maxwell RSC simplyRNA Cells Kit and a
16 Maxwell RSC Instrument (Promega). After quality check by Agilent 2100 and Qubit 2.0,
17 the mRNA was enriched using oligo(dT) beads and rRNA removed using the Ribo-Zero
18 kit. The mRNA was fragmented randomly by adding fragmentation buffer; then, cDNA
19 was synthesized by using the mRNA template and random hexamers primers, followed
20 by addition of a custom second-strand synthesis buffer (Illumina), dNTPs, RNase H and
21 DNA polymerase I to initiate second-strand synthesis. Second, after a terminal repair, A
22 ligation, and sequencing adaptor ligation, the double-stranded cDNA library was
23 completed through size selection and PCR enrichment. Sequencing was performed
24 using 150-bp paired-end reads on a NovaSeq6000 (Illumina). Fastq files were aligned to
25 the GRCh38/hg38 genome by STAR. Gene read counts were quantified by STAR
26 quantMode GeneCounts function. The aligned BAM files were loaded into the Integrated
27 Genomics Viewer and visualized using a Sashimi plot for mRNA splicing analysis.

28

29 qRT-PCR

30 RNA was isolated from culture fibroblasts using FastGene RNA Basic Kit. The isolated
31 RNA was reverse-transcribed to cDNA using ReverTra Ace® qPCR RT Master Mix
32 (TOYOBO) according to manufacturer's instructions. The synthesized cDNA was used
33 as a template for qRT-PCR in a 7500 Fast Real-Time PCR System (Thermo Fisher
34 Scientific) using THUNDERBIRD® Probe One-step qRT-PCR Kit (TOYOBO). Primer
35 sequences are as follows: *ECHS1*-F, 5'-GTCTTCAGGGCCTGGTTGAG-3', *ECHS1*-R,
36 5'-CTGTGCAAACCTGGGCCTTCT-3', *ACTB*-F, 5'-GCGAGAAGATGACCCAGATC-3',

1 ACTB-R, 5'-GGATAGCACAGCCTGGATAG-3'.

2

3 Sanger sequencing

4 The *ECHS1* variants of patients and family members were sequenced by Sanger
5 sequencing. PCR products were directly sequenced using BigDye v3.1 Terminators
6 (Applied Biosystem, ThermoFisher Scientific) or SupreDye v3.1 reagent (Edge
7 BioSystems) and ABI 3130XL (Applied Biosystems, ThermoFisher Scientific).

8

9 Proteome

10 Samples from fibroblasts were prepared as described previously (Borna *et al*, 2019). The
11 samples were measured in both data-dependent and data-independent modes
12 performed on the Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific) as
13 previously described (Borna *et al*, 2019). Finally, 5,979 proteins were detected in 16
14 samples including two healthy controls and 14 mitochondrial disease patients. Then,
15 outlier protein expression analysis was performed using OUTRIDER (Brechtmann *et al*,
16 2018).

17

18 Immunoblotting analysis

19 SDS-PAGE and western blot were performed as previously described (Kohda *et al*,
20 2016). To isolate mitochondria, cell pellets were suspended in mitochondria isolation
21 buffer A (220 mM mannitol, 20 mM HEPES, 70 mM sucrose, 1 mM EDTA, pH 7.4, 2
22 mg/mL bovine serum albumin, 1× protease inhibitor cocktail) and homogenized with 20
23 strokes on ice. Homogenates were separated into cytosolic and nuclear fractions after
24 centrifugation at 700 g for 5 min at 4°C. The supernatants were centrifuged at 10,000 g
25 for 10 min at 4°C. Mitochondrial pellets were rinsed twice with mitochondria isolation
26 buffer B (220 mM mannitol, 20 mM HEPES, 70 mM sucrose, 1 mM EDTA, pH 7.4, 1×
27 protease inhibitor cocktail). Then, mitochondrial protein levels were determined using a
28 bicinchoninic acid assay. For SDS-PAGE analyses, enriched mitochondria were
29 solubilized in RIPA buffer (Nacalai Tesque, Japan) and denatured for 5 min at 95°C.
30 Prepared samples were separated by electrophoresis on 10% or 15% SDS-PAGE gels,
31 depending on the size of the detected protein. Each antibody was obtained as follows;
32 ECHS1 (11305-1-AP, Proteintech, IL, USA), GAPDH (G9545, Sigma-Aldrich), beta-actin
33 (A5441, Sigma-Aldrich).

34

35 Ethics statement

36 The studies were approved by the regional Ethics Committees at Juntendo University,

1 Saitama Medical University, and Chiba Children's Hospital, Kindai University. We
2 obtained written informed consent from the parents. All methods were performed in
3 accordance with relevant guidelines and regulations.

4

5 **Statistics**

6 Data are expressed as the mean \pm SEM. The statistical significance of differences was
7 determined by one-way ANOVA followed by Dunnet's test using Prism 9 (GraphPad
8 Software Inc., CA, USA).

9

10

11 **Data availability**

12 Raw data are available from the corresponding author upon reasonable request. ECHS1
13 knockout cells can also be distributed. Some genomic information that could be used to
14 identify individuals cannot be shared due to ethical restrictions.

15

16 **Acknowledgments**

17 We thank the family for their participation in the research presented here and the
18 Laboratory of Molecular and Biochemical Research, Biomedical Research Core
19 Facilities, Juntendo University Graduate School of Medicine, and Kasumi Kanai for
20 technical assistance. This work was supported by a grant for the Practical Research
21 Project for Rare/Intractable Diseases from AMED to H.O., K.M., Y.O. and A.O. (Fund ID:
22 JP21im0210625, JP21ek0109511, JP22ek0109485, JP22ek0109468, JP22gk0110038,
23 JP19ek0109273), Program for Promoting Platform of Genomics based Drug Discovery
24 to Y.O. (Fund ID: JP22kk0305015), the Research Center Network for Realization of
25 Regenerative Medicine (The Acceleration Program for Intractable Diseases Research
26 utilizing Disease-specific iPS cells, JP21bm0804018), and JSPS KAKENHI JP19H03624
27 to Y.O. and JP20H03648 to H.O.

28

29 **Author contributions**

30 YK, AS and YO wrote the manuscript. YK, AS, TK, TE, TM, MS, NI, YN, HN, YY and YW
31 performed the experiments. YK, AS, TK, TE, TM, MS, NI, YN, HN, YY, AIO, YW and YO
32 analyzed the data. TK, TE, TM, MS, TF, HO, AO and KM acquired clinical information.
33 YK, AS, TF, KRN and AIO did bioinformatics and statistical analysis. YK, AS and AO
34 supervised the study. All authors discussed the results and commented on the
35 manuscript.

36

1 **Disclosure and competing interests statement**

2 The authors declare no competing interests.

3

1 **References**

- 2 Borna NN, Kishita Y, Kohda M, Lim SC, Shimura M, Wu Y, Mogushi K, Yatsuka Y,
3 Harashima H, Hisatomi Y, *et al* (2019) Mitochondrial ribosomal protein PTCD3
4 mutations cause oxidative phosphorylation defects with Leigh syndrome.
5 *Neurogenetics* 20: 9–25
- 6 Brechtmann F, Mertes C, Matusevičiūtė A, Yépez VA, Avsec Ž, Herzog M, Bader DM,
7 Prokisch H & Gagneur J (2018) OUTRIDER: A Statistical Method for Detecting
8 Aberrantly Expressed Genes in RNA Sequencing Data. *Am J Hum Genet* 103:
9 907–917
- 10 Burgin HJ & McKenzie M (2020) Understanding the role of OXPHOS dysfunction in the
11 pathogenesis of ECHS1 deficiency. *FEBS Lett* 594: 590–610
- 12 D’Annibale OM, Koppes EA, Alodaib AN, Kochersperger C, Karunanidhi A, Mohsen
13 AW & Vockley J (2021) Characterization of variants of uncertain significance in
14 isovaleryl-CoA dehydrogenase identified through newborn screening: An
15 approach for faster analysis. *Mol Genet Metab* 134: 29–36
- 16 D’Annibale OM, Koppes EA, Sethuraman M, Bloom K, Mohsen AW & Vockley J (2022)
17 Characterization of exonic variants of uncertain significance in very long-chain
18 acyl-CoA dehydrogenase identified through newborn screening. *J Inherit Metab*
19 *Dis*: 1–12
- 20 Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, Janizek JD, Huang
21 X, Starita LM & Shendure J (2018) Accurate classification of BRCA1 variants with
22 saturation genome editing. *Nature* 562: 217–222
- 23 Haack TB, Jackson CB, Murayama K, Kremer LS, Schaller A, Kotzaeridou U, de Vries
24 MC, Schottmann G, Santra S, Büchner B, *et al* (2015a) Deficiency of ECHS1
25 causes mitochondrial encephalopathy with cardiac involvement. *Ann Clin Transl*
26 *Neurol*: n/a-n/a
- 27 Haack TB, Jackson CB, Murayama K, Kremer LS, Schaller A, Kotzaeridou U, de Vries
28 MC, Schottmann G, Santra S, Büchner B, *et al* (2015b) Deficiency of ECHS1
29 causes mitochondrial encephalopathy with cardiac involvement. *Ann Clin Transl*
30 *Neurol*: 492–509
- 31 Kohda M, Tokuzawa Y, Kishita Y, Nyuzuki H, Moriyama Y, Mizuno Y, Hirata T, Yatsuka
32 Y, Yamashita-Sugahara Y, Nakachi Y, *et al* (2016) A Comprehensive Genomic
33 Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain
34 Complex Deficiencies. *PLoS Genet* 12: 1–31
- 35 Kuwajima M, Kojima K, Osaka H, Hamada Y, Jimbo E, Watanabe M, Aoki S, Sato-
36 Shirai I, Ichimoto K, Fushimi T, *et al* (2021) Valine metabolites analysis in ECHS1

- 1 deficiency. *Mol Genet Metab Reports* 29
- 2 Kweon J, Jang AH, Shin HR, See JE, Lee W, Lee JW, Chang S, Kim K & Kim Y (2020)
- 3 A CRISPR-based base-editing screen for the functional assessment of BRCA1
- 4 variants. *Oncogene* 39: 30–35
- 5 Lee JS, Yoo T, Lee M, Lee Y, Jeon E, Kim SY, Lim BC, Kim KJ, Choi M & Chae JH
- 6 (2020) Genetic heterogeneity in Leigh syndrome: Highlighting treatable and novel
- 7 genetic causes. *Clin Genet* 97: 586–594
- 8 Naito Y, Hino K, Bono H & Ui-Tei K (2015) CRISPRdirect: Software for designing
- 9 CRISPR/Cas guide RNA with reduced off-target sites. *Bioinformatics* 31: 1120–
- 10 1123
- 11 Ogawa E, Fushimi T, Ogawa-Tominaga M, Shimura M, Tajika M, Ichimoto K,
- 12 Matsunaga A, Tsuruoka T, Ishige M, Fuchigami T, *et al* (2020) Mortality of
- 13 Japanese patients with Leigh syndrome: Effects of age at onset and genetic
- 14 diagnosis. *J Inherit Metab Dis* 43: 819–826
- 15 Ogawa E, Shimura M, Fushimi T, Tajika M, Ichimoto K, Matsunaga A, Tsuruoka T,
- 16 Ishige M, Fuchigami T, Yamazaki T, *et al* (2017) Clinical validity of biochemical
- 17 and molecular analysis in diagnosing Leigh syndrome: a study of 106 Japanese
- 18 patients. *J Inherit Metab Dis* 40: 685–693
- 19 Peters H, Buck N, Wanders R, Ruiter J, Waterham H, Koster J, Yapliito-Lee J,
- 20 Ferdinandusse S & Pitt J (2014) ECHS1 mutations in Leigh disease: A new inborn
- 21 error of metabolism affecting valine metabolism. *Brain* 137: 2903–2908
- 22 Peters H, Ferdinandusse S, Ruiter JP, Wanders RJA, Boneh A & Pitt J (2015)
- 23 Metabolite studies in HIBCH and ECHS1 defects: Implications for screening. *Mol*
- 24 *Genet Metab* 115: 168–173
- 25 Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA & Zhang F (2013) Genome
- 26 engineering using the CRISPR-Cas9 system. *Nat Protoc* 8: 2281–2308
- 27 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M,
- 28 Lyon E, Spector E, *et al* (2015) Standards and guidelines for the interpretation of
- 29 sequence variants: A joint consensus recommendation of the American College of
- 30 Medical Genetics and Genomics and the Association for Molecular Pathology.
- 31 *Genet Med* 17: 405–424
- 32 Robinson BH, Petrova-Benedict R, Buncic JR & Wallace DC (1992) Nonviability of cells
- 33 with oxidative defects in galactose medium: A screening test for affected patient
- 34 fibroblasts. *Biochem Med Metab Biol* 48: 122–126
- 35 Sakai C, Yamaguchi S, Sasaki M, Miyamoto Y, Matsushima Y & Goto Y ichi (2015)
- 36 ECHS1 mutations cause combined respiratory chain deficiency resulting in leigh

- 1 syndrome. *Hum Mutat* 36: 232–239
- 2 Sato-Shirai I, Ogawa E, Arisaka A, Osaka H, Murayama K, Kuwajima M, Watanabe M,
3 Ichimoto K, Ohtake A & Kumada S (2021) Valine-restricted diet for patients with
4 ECHS1 deficiency: Divergent clinical outcomes in two Japanese siblings. *Brain*
5 *Dev* 43: 308–313
- 6 Sharpe AJ & McKenzie M (2018) Mitochondrial fatty acid oxidation disorders
7 associated with short-chain enoyl-CoA hydratase (ECHS1) deficiency. *Cells* 7: 1–
8 13
- 9 Simon MT, Eftekharian SS, Ferdinandusse S, Tang S, Naseri T, Reupena MS,
10 McGarvey ST, Minster RL, Weeks DE, Nguyen DD, *et al* (2021) ECHS1 disease
11 in two unrelated families of Samoan descent: Common variant - rare disorder. *Am*
12 *J Med Genet Part A* 185: 157–167
- 13 Stenton SL, Zou Y, Cheng H, Liu Z, Wang J, Shen D, Jin H, Ding C, Tang X, Sun S, *et*
14 *al* (2022) Leigh Syndrome: A Study of 209 Patients at the Beijing Children’s
15 Hospital
- 16 Tadaka S, Hishinuma E, Komaki S, Motoike IN, Kawashima J, Saigusa D, Inoue J,
17 Takayama J, Okamura Y, Aoki Y, *et al* (2021) jMorp updates in 2020: Large
18 enhancement of multi-omics data resources on the general Japanese population.
19 *Nucleic Acids Res* 49: D536–D544
- 20 Tadaka S, Katsuoka F, Ueki M, Kojima K, Makino S, Saito S, Otsuki A, Gocho C,
21 Sakurai-Yageta M, Danjoh I, *et al* (2019) 3.5KJPNv2: an allele frequency panel of
22 3552 Japanese individuals including the X chromosome. *Hum Genome Var* 6
- 23 Tetreault M, Fahiminiya S, Antonicka H, Mitchell GA, Geraghty MT, Lines M, Boycott
24 KM, Shoubridge EA, Mitchell JJ, Michaud JL, *et al* (2015) Whole-exome
25 sequencing identifies novel ECHS1 mutations in Leigh syndrome. *Hum Genet*
26 134: 981–991
- 27 Uchino S, Iida A, Sato A, Ishikawa K, Mimaki M, Nishino I & Goto Y ichi (2019) A novel
28 compound heterozygous variant of ECHS1 identified in a Japanese patient with
29 Leigh syndrome. *Hum Genome Var* 6: 6–9
- 30 Vaca Jacome AS, Rabilloud T, Schaeffer-Reiss C, Rompais M, Ayoub D, Lane L,
31 Bairoch A, Van Dorsselaer A & Carapito C (2015) N-terminome analysis of the
32 human mitochondrial proteome. *Proteomics* 15: 2519–2524
- 33 Xia C, Lou B, Fu Z, Mohsen AW, Shen AL, Vockley J & Kim JJP (2021) Molecular
34 mechanism of interactions between ACAD9 and binding partners in mitochondrial
35 respiratory complex I assembly. *iScience* 24: 103153
- 36 Yamada K, Aiba K, Kitaura Y, Kondo Y, Nomura N, Nakamura Y, Fukushi D,

- 1 Murayama K, Shimomura Y, Pitt J, *et al* (2015) Clinical, biochemical and
- 2 metabolic characterisation of a mild form of human short-chain enoyl-CoA
- 3 hydratase deficiency: Significance of increased n-acetyl-s-(2-
- 4 carboxypropyl)cysteine excretion. *J Med Genet* 52: 691–698
- 5 Yang H & Yu D (2020) Clinical, biochemical and metabolic characterization of patients
- 6 with short-chain enoyl-CoA hydratase(ECHS1) deficiency: Two case reports and
- 7 the review of the literature. *BMC Pediatr* 20: 1–10
- 8

1 **Figures**

2

3 **Figure 1. Summary of *ECHS1* variants**

4 Gene structure (top) and corresponding amino acids (bottom) of *ECHS1*. Variants
5 registered r as pathogenic (red) and likely pathogenic (yellow) in ClinVar, and jMorp
6 (square) are shown. The two underlined variants were identified from our genomic
7 analysis study; no experimental VUS verification was performed.

8

9 **Figure 2. Characterization of *ECHS1* KO cells.**

10 A. Genomic analysis of *ECHS1* KO cells by Sanger sequencing.

11 B. *ECHS1* expression levels in WT and *ECHS1* KO HEK293FT cells quantified by qRT-
12 PCR. Whole cell extracts from WT and *ECHS1* KO HEK293FT cells analyzed by
13 immunoblotting using the indicated antibodies. Single and double asterisks indicate
14 uncleaved and cleaved forms, respectively.

15 C. ATP assay of WT and *ECHS1* KO HEK293FT cells cultured in glucose or galactose
16 medium. The graph shows the ATP level in galactose medium divided by galactose.

17 D. ATP assay of WT and *ECHS1* KO HEK293FT cells treated with the indicated L-valine
18 concentrations. Bar graphs represent the average ATP level in each condition from three
19 biological independent experiments. Error bars, \pm SEM. Statistical analysis was
20 performed using ANOVA followed by Dunnet's test. RLU, relative luciferase unit.

21

22 **Figure 3. Validation of *ECHS1* VUS.**

23 WT and *ECHS1* KO HEK293FT cells transfected with the indicated expression vectors
24 subjected to immunoblotting analysis (A) and ATP assay (B).

25 A. Whole cell extracts were analyzed by immunoblotting using the indicated antibodies.
26 Single and double asterisks indicate uncleaved and cleaved forms, respectively.

27 B. ATP assay 4 days after treatment with L-valine (0.8 mM). Bar graphs represent the
28 average ATP level in each condition from three biological independent experiments. Error
29 bars, \pm SEM. Red bars, pathogenic variants. Gray bars, VUS. RLU, relative luciferase
30 unit.

31 C. Statistical analysis of Figure B using ANOVA followed by Dunnet's test. The color
32 scale shows the P value compared with vector (vs Vec, statistically different red to blue)
33 and WT *ECHS1* (vs WT, statistically different blue to red).

34

35 **Figure 4. Validation of *ECHS1* VUS compound hetero.**

36 A. Whole cell extracts from WT and *ECHS1* KO HEK293FT cells transfected with the

1 indicated expression vectors analyzed by immunoblotting using the indicated antibodies.
2 B. ATP assay of *ECHS1* KO HEK293FT cells expressing the indicated expression
3 vectors treated with additional L-valine (0.8 mM) for four days. Bar graphs represent the
4 average ATP level in each condition from three biological independent experiments. Error
5 bars, SEM. RLU, relative luciferase unit.
6 C. Statistical analysis of Figure B using ANOVA followed by Dunnet's test. The color
7 scale shows the P value compared with vector (vs Vec, statistically different red to blue)
8 and WT *ECHS1* (vs WT, statistically different blue to red).

9

10 **Figure 5. Abnormal splicing and allele-biased gene expression**

11 A. RNA-seq data from two patients with c.489G>A (p.P163=) showing reads suggestive
12 of splicing abnormalities in exons with c.489G>A.
13 B. Read counts of the *ECHS1* gene are plotted on the horizontal axis and the number of
14 detected exon skipping is plotted on the vertical axis. Gene counts were calculated by
15 STAR, and the number of exon skipping was extracted from the Sashimi plot data.
16 C. Ratio of c.489G>A and c.796A>C and c.832G>A variants on the IGV viewer. In two
17 cases, the allele expression with c.489G>A was decreased.

18

19 **Figure 6. ECHS1 protein status in the patient with Pro163= and Ala278Thr**

20 A. OUTRIDER analysis illustrating protein expression in a volcano plot. *ECHS1* was
21 detected as a protein with a large decrease in expression.
22 B. Western blotting for *ECHS1* in patients with *ECHS1* mutations and controls.
23 Compared to previously reported *ECHS1* cases, case 1 showed significantly reduced
24 *ECHS1* expression. β -actin was detected as a loading control.

25

1 **Tables**

2

Patient ID	DNA (NM_004092.4)	Protein(NP_004083.3)
0207	c.5C>T	p.Ala2Val
0207	c.176A>G	p.Asn59Ser
0255	c.176A>G	p.Asn59Ser
0255	c.413C>T	p.Ala138Val
0346ESc	c.176A>G	p.Asn59Ser
0346ESc	c.476A>G	p.Gln159Arg
0346YSc	c.176A>G	p.Asn59Ser
0346YSc	c.476A>G	p.Gln159Arg
0376	c.98T>C	p.Phe33Ser
0376	c.176A>G	p.Asn59Ser
0536	c.1A>G	p.Met1Val
0536	c.5C>T	p.Ala2Val
0775	c.5C>T	p.Ala2Val
0775	c.88+2T>C	
1038ESc	c.5C>T	p.Ala2Val
1038ESc	c.176A>G	p.Asn59Ser
1038YSc	c.5C>T	p.Ala2Val
1038YSc	c.176A>G	p.Asn59Ser
1135ESc	c.5C>T	p.Ala2Val
1135ESc	c.176A>G	p.Asn59Ser
1135YSc	c.5C>T	p.Ala2Val
1135YSc	c.176A>G	p.Asn59Ser
1553	c.5C>T	p.Ala2Val
1553	c.176A>G	p.Asn59Ser
2521	c.23T>C	p.Leu8Pro
2521	c.176A>G	p.Asn59Ser
2637	c.5C>T	p.Ala2Val
2637	c.176A>G	p.Asn59Ser
2816	c.23T>C	p.Leu8Pro
2816	c.176A>G	p.Asn59Ser

3 **Table 1. *ECHS1* variants identified from genomic analysis**

4

Case	Sex	Onset	Symptoms	Complex deficiency	OCR	Var 1	Var 2
1	female	> 1 y	poor suckling, metabolic acidosis	CIV 26.1% (Fb)	68% (Fb)	c.796A>C (p.Thr266Pro)	c.489G>A (p.Pro163=)
2	male	≤ 1 y	gait disorder, nystagmus, MR, MRI abnormality	Normal (Fb)	N.T.	c.802G>A (p.Ala268Thr)	c.489G>A (p.Pro163=)
3	male	≤ 1 y	listlessness, mental retardation, regression after exanthema subitum, abnormality, deafness, fatigue, hypotonia	Normal (Fb)	36% (Fb)	c.832G>A (p.Ala278Thr)	c.489G>A (p.Pro163=)
4	male	> 1 y	developmental delay, convulsion, abnormalities, regression	Normal (Fb)	54% (Fb)	c.832G>A (p.Ala278Thr)	c.489G>A (p.Pro163=)
5	male	> 1 y	Leigh syndrome, increase of 2-methyl-2,3-dihydroxybutyric acid	Normal (Fb)	58% (Fb)	c.833C>T (p.Ala278Val)	c.489G>A (p.Pro163=)

1
2
3
4
5
6

Table 2. Patient summary of cases with *ECHS1* variants

Fb: Fibroblast, CIV: Mitochondrial respiratory chain complex IV, OCR: oxygen consumption rates. Complex enzyme activity was defined by <40% decrease. For OCR, a value <71.6% was used as diagnostic criterion.




Figure 1






Figure 2

A



B




C

	Vec	WT	M1V	M1T	A2V	L8P	F33S	N59S	D63N	K74E	H119Q	L145P	P163L	T266P	A268T	R272Q	A278T
vs Vec	-	0.0015	0.6909	0.9888	0.9008	0.2205	0.0089	0.9997	0.0246	<0.0001	0.6735	0.9309	0.4297	0.0077	0.4514	0.0583	0.9953
vs WT	0.0015	-	0.0762	0.0158	0.0351	0.3391	0.999	0.0027	0.956	0.4807	0.0803	<0.0001	0.1651	0.9991	0.1547	0.7744	0.0002


Deleterious Benign

Figure 3

A



B




C

	Vec	WT	A2V	L8P	F33S	N59S	N59S+ Vec	N59S+ WT	N59S+ A2V	N59S+ L8P	N59S+ F33S
vs Vec		0.0001	0.2601	0.0031	0.0001	0.6689	0.9541	0.0003	0.3122	0.1256	0.0639
vs WT	0.0001		0.0008	0.0916	0.9895	0.0002	0.0001	0.4773	0.0006	0.0021	0.0047




Figure 4

A



B



C





Figure 5

A



B




Figure 6